APLS icon

Apellis Pharmaceuticals

16.70 USD
-0.58
3.36%
At close May 14, 4:00 PM EDT
Pre-market
16.68
-0.02
0.12%
1 day
-3.36%
5 days
-6.23%
1 month
-13.61%
3 months
-39.05%
6 months
-40.48%
Year to date
-49.64%
1 year
-59.47%
5 years
-44.96%
10 years
19.03%
 

About: Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.

Employees: 710

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

212% more call options, than puts

Call options by funds: $104M | Put options by funds: $33.5M

37% more repeat investments, than reductions

Existing positions increased: 97 | Existing positions reduced: 71

20% more capital invested

Capital invested by funds: $3.38B [Q3] → $4.04B (+$667M) [Q4]

5.73% more ownership

Funds ownership: 96.14% [Q3] → 101.87% (+5.73%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 6 [Q3] → 6 (+0) [Q4]

2% less first-time investments, than exits

New positions opened: 60 | Existing positions closed: 61

2% less funds holding

Funds holding: 261 [Q3] → 257 (-4) [Q4]

Research analyst outlook

13 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$18
8%
upside
Avg. target
$35
108%
upside
High target
$57
241%
upside

13 analyst ratings

positive
46%
neutral
54%
negative
0%
Mizuho
Graig Suvannavejh
42% 1-year accuracy
8 / 19 met price target
20%upside
$20
Neutral
Maintained
14 May 2025
Raymond James
Ryan Deschner
91% 1-year accuracy
10 / 11 met price target
211%upside
$52
Outperform
Downgraded
9 May 2025
B of A Securities
Tazeen Ahmad
29% 1-year accuracy
9 / 31 met price target
38%upside
$23
Neutral
Downgraded
9 May 2025
RBC Capital
Luca Issi
20% 1-year accuracy
11 / 55 met price target
8%upside
$18
Sector Perform
Maintained
8 May 2025
Scotiabank
Greg Harrison
32% 1-year accuracy
13 / 41 met price target
20%upside
$20
Sector Perform
Maintained
8 May 2025

Financial journalist opinion

Based on 10 articles about APLS published over the past 30 days

Negative
Zacks Investment Research
6 days ago
Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down
APLS stock falls as it reports weaker-than-expected first-quarter 2025 results, wherein both earnings and revenues miss estimates.
Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down
Negative
The Motley Fool
1 week ago
Why Apellis Pharmaceuticals Wilted on Wednesday
A big quarterly earnings miss was the news driving down the value of Apellis Pharmaceuticals (APLS -5.99%) stock in the middle of the trading week. Investors didn't take this development well, and they collectively pushed down Apellis by almost 6%, on a day when the S&P 500 (^GSPC 0.43%) closed in the black with a 0.4% gain.
Why Apellis Pharmaceuticals Wilted on Wednesday
Neutral
Seeking Alpha
1 week ago
Apellis Pharmaceuticals, Inc. (APLS) Q1 2025 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q1 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants Tracy Vineis – Vice President-Communications Cedric Francois – Co-Founder and Chief Executive Officer Tim Sullivan – Chief Financial Officer David Acheson – Executive Vice President-Commercial Caroline Baumal – Chief Medical Officer Conference Call Participants Jon Miller – Evercore Tazeen Ahmad – Bank of America Securities Anupam Rama – JPM Steve Seedhouse – Cantor Colleen Kusy – Baird Eliana Merle – UBS Annabel Samimy – Stifel Biren Amin – Piper Sandler Yigal Nochomovitz – Citigroup Douglas Tsao – H.C. Wainwright Lachlan Hanbury-Brown – William Blair Ryan Deschner – Raymond James Judah Frommer – Morgan Stanley Greg Harrison – Scotiabank Graig Suvannavejh – Mizuho Securities Lisa Walter – RBC Operator Hello, everyone.
Apellis Pharmaceuticals, Inc. (APLS) Q1 2025 Earnings Call Transcript
Positive
Zacks Investment Research
1 week ago
Apellis Pharmaceuticals (APLS) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Apellis Pharmaceuticals (APLS) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Apellis Pharmaceuticals (APLS) Reports Q1 Earnings: What Key Metrics Have to Say
Negative
Zacks Investment Research
1 week ago
Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Lags Revenue Estimates
Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.54 per share a year ago.
Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Lags Revenue Estimates
Neutral
GlobeNewsWire
1 week ago
Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results
WALTHAM, Mass., May 07, 2025 (GLOBE NEWSWIRE) --  Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its first quarter 2025 financial results and business highlights.
Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results
Neutral
GlobeNewsWire
1 week ago
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will participate in the following May investor conferences: BofA Securities 2025 Healthcare Conference: Fireside chat on Tuesday, May 13, 2025 at 8:40 a.m.
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Neutral
GlobeNewsWire
2 weeks ago
Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results
WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its first quarter 2025 financial results on Wednesday, May 7, 2025, at 8:30 a.m.
Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results
Negative
Zacks Investment Research
2 weeks ago
Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Neutral
GlobeNewsWire
3 weeks ago
Apellis Announces Craig Wheeler to Join the Board of Directors
WALTHAM, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that Craig Wheeler, founder and chief executive officer of Headwaters Biotech Advisors, will join the Apellis Board of Directors, effective immediately. Mr. Wheeler is a highly accomplished executive with more than 30 years of leadership experience across the biopharmaceutical industry.
Apellis Announces Craig Wheeler to Join the Board of Directors
Charts implemented using Lightweight Charts™